Wiping Out Wheezing: Novel Therapeutic Targets for Patients with Severe Asthma
- 1 December 2020
- journal article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 202 (11) , 1576-1578
Abstract
In 2003, the first biologic therapy (omalizumab) for asthma was U.S. Food and Drug Administration approved and immediately revolutionized the treatment of patients with severe asthma, including patients with evidence of type 2 (T2) inflammation. In the years since approval, additional monoclonal antibodies against T2-high asthma targets have widened the therapeutic landscape and include antagonists to IL-5 (mepolizumab and reslizumab), the IL-5 receptor (benralizumab), and the IL-4 receptor (dupilumab). These medications have shown considerable efficacy, yet some patients with severe asthma have no initial response, cannot tolerate the adverse reactions, or lose therapeutic response with time. Although there are many medications in development to improve asthma management, the following articles outline three new promising and not-so-promising approaches for the treatment of severe T2-high asthma.Keywords
This publication has 6 references indexed in Scilit:
- Same Target, Different Therapeutic Outcomes: The Case of CAY10471 and Fevipiprant on CRTh2 Receptor in Treatment of Allergic Rhinitis and AsthmaCombinatorial Chemistry & High Throughput Screening, 2019
- Fevipiprant, an oral prostaglandin DP2receptor (CRTh2) antagonist, in allergic asthma uncontrolled on low-dose inhaled corticosteroidsEuropean Respiratory Journal, 2017
- The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthmaPulmonary Pharmacology & Therapeutics, 2016
- Prostaglandin D2 pathway upregulation: Relation to asthma severity, control, and TH2 inflammationJournal of Allergy and Clinical Immunology, 2013
- The DP receptor, allergic inflammation and asthmaProstaglandins, Leukotrienes and Essential Fatty Acids, 2003
- Prostaglandin D2 Selectively Induces Chemotaxis in T Helper Type 2 Cells, Eosinophils, and Basophils via Seven-Transmembrane Receptor Crth2Journal of Experimental Medicine, 2001